Table of Contents
ISRN Hematology
Volume 2013, Article ID 904201, 7 pages
Clinical Study

Survival and Prognostic Factors for AIDS and Non-AIDS Patients with Non-Hodgkin’s Lymphoma in Bahia, Brazil: A Retrospective Cohort Study

1Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Rua Augusto Viana s/n, 40110-060 Salvador, BA, Brazil
2Serviço de Hematologia, Núcleo de Oncologia da Bahia, Avenida Adhemar de Barros 123, Ondina, 40170-110 Salvador, BA, Brazil

Received 21 June 2013; Accepted 7 August 2013

Academic Editors: Z. Duan and Y. K. Lee

Copyright © 2013 Estela Luz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Despite the benefits of HAART, HIV-infected patients are increasingly affected by different malignancies. We compared a 5-year-period survival time and prognostic factors for HIV-1-infected individuals diagnosed with non-Hodgkin lymphomas (NHL) in a nested case-control study, with non-HIV-infected individuals in Salvador, Brazil. Survival time and prognostic factors were compared to HIV-negative patients. 31 cases (versus 63 controls) had a significantly more advanced NHL at diagnosis and lower mean CD4 count (26 cells/mm3) than controls. Mean overall survival (OS) was 35.8 versus 75.4 months, for cases and controls, respectively ( ), while mean event-free survival time (EFS) was 34.5 months for cases, versus 68.8 for controls ( ). Higher IPI, increased LDH levels, bone marrow infiltration, lower absolute lymphocyte counts (<1,000 cells/mm3), and type B symptoms were associated with a shorter survival time for cases. Although patients without poorer prognostic factors at baseline had an OS comparable to controls, the mean CD4 cell count for cases was similar for patients with favorable and nonfavorable response to therapy. Our findings suggest that HIV-1 infection is significantly associated with a shorter survival time for patients with NHL, independently of other predictive factors and of disease stage.